HOME >> BIOLOGY >> NEWS
SFU Spin-Off Company To Research Promising Antibacterial Agents

A Simon Fraser University professor's research into new chemical structures that may combat antibiotic-resistant bacteria has attracted a $750,000 round of financing led by the Western Technology Seed Investment Fund (WTSIF). The deal, fostered by SFU's University/Industry Liaison Office, includes formation of a new spin-off company, Chirologix Pharmaceuticals Inc.

Saul Wolfe, an organic chemistry professor who holds some 40 patents in the field of antibiotics research, will serve as Chief Scientific Officer of the new company, which he has co-founded with Hugh MacNaught of WTSIF, who will hold the position of president and CEO.

"WTSIF reviews about 250 technologies a year and invests in about five of them," says MacNaught. Wolfe's research attracted attention, he says, because of the worldwide concern about antibiotic-resistant bacteria. "Antibiotics are a $25 billion (U.S.) annual market," he says. "When Dr. Wolfe synthesizes compounds effective against resistant strains of bacteria, clinical practice will benefit significantly, and the commercial potential will be immense."

SFU's University/Industry Liaison Office director Michael Volker is optimistic about this latest spin-off company, in which SFU holds an equity interest. "We often have promising technologies," he says, "but here we have all three components needed for the first stage of forming a real company - technology, investment and management."


'"/>

Contact: Deborah Stupnikoff
deborah-stupnikoff@sfu.ca
604-291-4985
Simon Fraser University
16-Apr-1999


Page: 1

Related biology news :

1. Ferr-Damar wins 2004 Eli Lilly and Company Research Award
2. Open access initiative from the Company of Biologists
3. ESA Corporate Award winner 2001: Weyerhaeuser Company Limited British Columbia Coastal Forest Project Team
4. Warner-Lambert Company gift creates bioinformatics program
5. New Company Formed Through Licensing Of Cardiac-Hypertrophy Technology From Texas Institutions
6. Move Over, Protein Kinase C, Youve Got Company: Munc13-1 Is A Novel Diacylglycerol Target That Modulates Neurotransmitter Release
7. Perkin-Elmer, Dr. J. Craig Venter, And TIGR Announce Formation Of New Genomics Company
8. New Company To Turn UNC-CH, Army Inventions Into Improved Vaccines
9. Florida Company Using ORNL Technology For Revolutionary Wheelchair
10. Researchers determine genetic cause of Timothy syndrome
11. Researchers find color sensitive atomic switch in bacteria

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – a community partnership ... to address substance use disorder (SUD) – will take center stage at ... to the program’s effectiveness in preventing and treating opioid abuse in Blair County, Pennsylvania, ...
(Date:11/14/2019)... ... 2019 , ... NDA Partners Chairman Carl Peck, MD ... program management executive with more than 33 years of regulatory and product development ... an Expert Consultant. , Robert Peterson has extensive experience in formulating and ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the leader in ... performance up to 25% and reduces cost-per-click by as much as 15%. An ... attribution (MTA) to predict best advertising outcomes and automatically allocate daily ad investments ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... Western University of ... innovation and technology play in educating the next generation of health care providers. ... and presentations by WesternU administrators and representatives of companies working with the University ...
(Date:10/26/2019)... ... October 24, 2019 , ... Sparks Marketing ... Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen the agency’s growing ... Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device and healthcare technologies ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, a clinical stage microbiome ... met its primary safety endpoints, with no application site reactions and no adverse ... treatment of interdigital tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical ...
(Date:10/10/2019)... (PRWEB) , ... October 09, 2019 , ... ... Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker ... October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and ...
Breaking Biology Technology:
Cached News: